3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
5
Carcinoma, Renal Cell
4
Squamous Cell Carcinoma of Head and Neck
3
Neoplasms
2
Lung Neoplasms
2
Urogenital Neoplasms
1
Solid Tumor, Adult
1
Recurrence
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Mesothelioma, Malignant
1
Meningeal Neoplasms
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Disease Progression
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Nivolumab
2
Ipilimumab
2
vedolizumab
1
gallium 68 PSMA-11
1
fludarabine
1
cabozantinib
1
aldesleukin
1
abiraterone
1
abemaciclib
1
Therapeutics
1
Specimen Handling
1
Prednisone
1
Prednisolone
1
Magnetic Resonance Spectroscopy
1
LDP-02
1
Interleukin-2
1
Infliximab
1
Immunoglobulin G
1
Geriatric Assessment
1
Fulvestrant
1
Exercise
1
Disulfides
1
Cyclophosphamide
1
CTLA-4 Antigen
1
CT-P13
1
Biopsy
1
Androgen Antagonists
1
Adrenal Cortex Hormones
1
(225)Ac-PSMA-617
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Urogenital Neoplasms
×
Interleukin-2
×
Clear all
NCT05902520
2026-01-08
ACT
AgonOx, Inc.
Phase 1
Active not recruiting
18 enrolled